Table S1: Baseline characteristics in patients with newly implanted pacemakers

|  |  |  |  |
| --- | --- | --- | --- |
|  | All (n=106) | Age ≤ 60 years (n=31) | Age > 60 years (n=75) |
| Age, years | 65.5 (16.8) | 43.1 (11.9) | 74.7 (6.7) |
| Sex, % female | 45.3 | 45.2 | 45.3 |
|  |  |  |  |
| Reported history |  |  |  |
|  Syncope, % | 98.1 | 100 | 97.3 |
|  Dizziness, n % | 68.3 | 48.4 | 76.7 |
|  Number of syncope episodes, md [range] | 7 [0-100] | 10 [1-100] | 5.5 [0-100] |
|  Duration of symptoms, md [range] | 7 [0-70] | 12 [0-40] | 5.5 [0-70] |
|  |  |  |  |
| SBP, mmHg | 139.1 (22.2) | 124.4 (14.9) | 145.2 (22.0) |
| DBP, mmHg | 71.4 (10.5) | 68.3 (8.5) | 72.7 (11.0) |
| Resting heart rate, bpm | 66.3 ((11.6) | 62.8 (8.3) | 67.7 (12.2) |
| eGFR, ml/min | 79.3 (27.8) | 104.8 (28.4) | 67.8 (18.5) |
| EF, % | 54 (3) | 54 (3) | 54 (3) |
|  |  |  |  |
| Hypertension, % | 39.4 | 9.7 | 52.1 |
| Antihypertensive therapy, % | 39.8 | 9.7 | 52.8 |
|  ACE-inhibitors, % | 10.7 | 3.2 | 13.9 |
|  ARB, % | 16.5 | 3.2 | 22.2 |
|  Thiazides, % | 10.7 | 0 | 15.3 |
|  Beta blockers, % | 14.6 | 6.5 | 18.1 |
| CAD, % | 7.8 | 0 | 11.1 |
| Atrial fibrillation, % | 10.4 | 0 | 14.7 |
| Heart failure, % | 6.8 | 6.5 | 6.9 |
| Displayed as mean (standard deviation) unless otherwise specified.md = median; SBP = systolic blood pressure; DBP = diastolic blood pressure; eGFR = estimated glomerular filtration rate; EF = ejection fraction; ACE-inhibitors = angiotensin converting enzyme inhibitors; ARB = angiotensin II receptor blockers; CAD = coronary artery disease. |
|  |  |  |  |

Table S2: Pacing indication in patients with newly implanted pacemakers

|  |  |  |  |
| --- | --- | --- | --- |
|  | All (n=106) | Age ≤ 60 years (n=31) | Age > 60 years(n=75) |
| Sinus arrest, n (%) | 72 (67.9) | 23 (74.2) | 49 (65.3) |
| Atrioventricular block, n (%) | 29 (27.4) | 7 (22.6) | 22 (29.3) |
| AF with bradycardia, n (%) | 3 (2.8) | 0 | 3 (4.0) |
| Sick sinus plus VT/VF, n (%) | 2 (1.9) | 1 (3.2) | 1 (1.3) |
| AF = atrial fibrillation; VT = ventricular tachycardia; VF = ventricular fibrillation; Sinus arrest without ventricular escape |
|  |  |  |  |

Table S3: Method used for determining pacemaker indication

|  |  |  |  |
| --- | --- | --- | --- |
|  | All (n=106) | Age ≤ 60 years (n=31) | Age > 60 years(n=75) |
| Resting ECG, (%) | 8 (7.5) | 1 (3.2) | 7 (9.3) |
| HUT including CSM, n (%) | 73 (68.7) | 23 (64.2) | 50 (68.9) |
|  Of which CSM | 32 (30.2) | 3 (9.7) | 32 (30.2) |
| Ambulatory ECG or telemetry, n (%) | 11 (10.4) | 3 (9.7) | 11 (10.4) |
| ICM, n (%) | 14 (13.2) | 4 (12.9) | 14 (13.2) |
| HUT = head-up-tilt test; CSM = carotid sinus massage; ICM = insertable cardiac monitor  |
|  |  |  |  |

Table S4: Reported syncope recurrence and diagnosis

|  |  |  |  |
| --- | --- | --- | --- |
|  | All (n=106) | Age ≤ 60 years (n=31) | Age > 60 years(n=75) |
| No syncope recurrence (%) | 91 (85.8) | 28 (90.3) | 63 (84.0) |
|  |  |  |  |
| Syncope recurrence | 15 (14.2) | 3 (9.7) | 12 (16.0) |
|  Orthostatic hypotension | 4 (26.7) | 0 | 4 (33.3) |
|  Vasovagal syncope | 4 (26.7) | 1 (33.3) | 3 (25.0) |
|  Tachyarrhythmia  | 1 (6.7) | 1 (33.3) | 0 |
|   |  |  |  |
|  EP, i.e. TLOC but not syncope | 1 (6.7) | 0 | 1 (8.3) |
|  Hypnotics overuse | 1 (6.7) | 0 | 1 (8.3) |
|  No diagnosis | 4 (26.7) | 1 (33.3) | 3 (25.0) |
|  |  |  |  |
| AF = atrial fibrillation; VT = ventricular tachycardia; VF = ventricular fibrillation; EP = electrophysiological; TLOC = transient loss of consciousness |
|  |  |  |  |